|
MiLOC Group Limited
Address : 2307,
23/F, Peninsula Tower,
538 Castle Peak Road, Cheung Sha Wan,
Kowloon, Hong Kong
E-mail :
info@miloc.com
Rorrico
Rorrico is a TCM product for the treatment of influenza viruses,
including the Influenza A virus and its sub-type virus, pandemic H1N1 or
Swine flu. Rorrico’s formula contains 21 herbs. It is confected with,
among other things, honeysuckle, radix isatidis, rhubarb, codonopsis
pilosula, amomum villosum, malt and white atractylodes medicine and has
the feature of heat-clearing and detoxification, blood stasis
detoxification and righting detoxification. |
 |
Clinical Trials
Initial tests on Rorrico indicate that it has antiviral efficacy on the
Influenza A (H1N1) virus, as evidenced by in-vitro research conducted by
the Wuhan Institute of Medical Virology in the PRC between May and
August 2009. The research states that Rorrico had the same effect as
Tamiflu on anti-virus replication and biosynthesis. Tamiflu is the most
frequently prescribed medicine for treating influenza.
MIAR of the Macau University of Science and Technology was commissioned
to conduct further clinical trials on human subjects to investigate the
therapeutic and preventative effects of Rorrico on influenza viruses, in
particular Influenza A viruses (including sub-type H1N1).
|
 |
 |
 |
Safety
Rorrico has passed safety testing conducted by the Chinese Medicines and
Food Safety Laboratory of MIAR, which is ISO/IEC 17025 accredited by the
National Association of Testing Authorities (Australia) (“NATA”). NATA
was created in 1947 and is a founding member of the International
Laboratory Accreditation Cooperation (ILAC) and the Asia Pacific
Laboratory Accreditation Cooperation (APLAC), and provides both of their
secretariats. The safety testing was conducted in accordance with the
safety compliance requirements for TCM distribution registration
established by the Department of Health, Macau. Rorrico will also need
to pass safety testing in Hong Kong and China as part of completing the
registration process in both of these jurisdictions. However, following
the successful completion of safety testing in Macau, the Directors are
confident that Rorrico will satisfy safety requirements in Hong Kong and
China. |
|
Tel : 2110 4221
Fax : 2110 4261 |
